Soliton, Inc. (SOLY): Price and Financial Metrics

Soliton, Inc. (SOLY): $22.58

0.03 (+0.13%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

F

SOLY Price/Volume Stats

Current price $22.58 52-week high $22.60
Prev. close $22.55 52-week low $7.40
Day low $22.56 Volume 1,380,300
Day high $22.59 Avg. volume 347,827
50-day MA $20.61 Dividend yield N/A
200-day MA $20.25 Market Cap 487.66M

SOLY Stock Price Chart Interactive Chart >


Soliton, Inc. (SOLY) Company Bio


Soliton, Inc. is a medical development company. It develops healthcare technological devices for medical and cosmetic treatments. The firm's devices generate planar acoustic waves or shock waves in cosmetic surgical procedures, aesthetic surgical procedures, and dermatology procedures for treatments. The company was founded by Walter V. Klemp & Christopher Capelli and is headquartered in Houston, TX.


SOLY Latest News Stream


Event/Time News Detail
Loading, please wait...

SOLY Latest Social Stream


Loading social stream, please wait...

View Full SOLY Social Stream

Latest SOLY News From Around the Web

Below are the latest news stories about Soliton Inc that investors may wish to consider to help them evaluate SOLY as an investment opportunity.

Allergan Aesthetics Completes Acquisition of Soliton

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today announced the successful completion of its acquisition of Soliton, Inc. (NASDAQ: SOLY). The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include a proven treatment for the appearance of cellulite.

Yahoo | December 16, 2021

Why Soliton Popped While the Market Slid Today

On a gloomy day for the stock market, healthcare aesthetics specialist Soliton (NASDAQ: SOLY) was a luminous bright spot on Tuesday. The company's shares rocketed almost 12% higher, on news that its absorption into soon-to-be-parent AbbVie (NYSE: ABBV) is about to close. With that out of the way, Soliton believes the acquisition will close "on or about" this Thursday, Dec. 16. The deal was first announced in mid-May. The two companies agreed that AbbVie's Allergan Aesthetics unit would acquire Soliton and its RESONIC device for $22.60 per share; all told, the enterprise value of the deal is around $550 million.

Yahoo | December 14, 2021

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates XOG, DSSI, SOLY, LMNX; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 17, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:Extraction Oil & Gas, Inc. (NASDAQ:XOG) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Bonanza Creek Energy, Inc.

Yahoo | May 17, 2021

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Soliton, Inc. - SOLY

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Soliton, Inc. ("SOLY" or the "Company") (SOLY) relating to its proposed acquisition by Allergan Aesthetics, an AbbVie company. Under the terms of the agreement, SOLY shareholders will receive $22.60 in cash per share.

Yahoo | May 15, 2021

Moore Kuehn Encourages LMNX, STPC, HCIC, and SOLY Investors to Contact Law Firm

Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:

Yahoo | May 14, 2021

Read More 'SOLY' Stories Here

SOLY Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 29.92%
5-year 207.21%
YTD N/A
2023 N/A
2022 N/A
2021 0.00%
2020 -30.05%
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!